<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531293</url>
  </required_header>
  <id_info>
    <org_study_id>EOP17</org_study_id>
    <nct_id>NCT04531293</nct_id>
  </id_info>
  <brief_title>Comparing Pressure Based and Dilution Based Total Lung Capacity Measurements in COPD Patients for Lung Function Diagnostics</brief_title>
  <official_title>Mono-centred, Controlled Cross-over Study Comparing Pressure Based, and Dilution Based Total Lung Capacity Measurements in COPD Patients and Healthy Subjects Using Two Commercially Available Devices for Lung Function Diagnostics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ndd Medizintechnik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ndd Medizintechnik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total Lung Capacity (TLC) of the lungs can be determined using a pressure based method (i.e.&#xD;
      by body plethysmography) or it can be determined using a dilution based method (i.e. by&#xD;
      single breath dilution during a CO diffusing capacity test). The results of the two methods&#xD;
      differ, especially in patients with higher grades of COPD. The study investigates an improved&#xD;
      analysis for the determination of TLC using the dilution method; this method has been&#xD;
      suggested in the new ATS/ERS DLCO (diffusion capacity of lung for carbon monoxide) standard&#xD;
      published in 2017. This study is based on approx. 120 participants. So far, there has not&#xD;
      been a study using commercially available equipment.&#xD;
&#xD;
      Spirometry, lung volume measurement by body plethysmography and DLCO measurements will be&#xD;
      performed on reference device (Masterscreen Body/Diff, Vyaire, USA), Spirometry and DLCO will&#xD;
      also be performed on the device under test (EasyOne Pro LAB, ndd Medizintechnik AG,&#xD;
      Switzerland) in a crossover design. Both devices are CE marked and FDA approved. The tests&#xD;
      performed on both devices are standardized tests performed routinely with patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Total Lung Capacity (TLC) measurement using total-breath method and standard method</measure>
    <time_frame>single measurement on day 1</time_frame>
    <description>Difference in Total Lung Capacity (TLC) using total-breath method (according to ATS/ERS standard 2017, EasyOne Pro) and TLC using normal dilution method (according to ATS/ERS standard 2005, EasyOne Pro) in relation to TLC using body plethysmography (Vyaire).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dependency between primary outcome and COPD disease severity</measure>
    <time_frame>single measurement on day 1</time_frame>
    <description>Correlation between ( TLC(dilution, total-breath, EasyOne Pro) - TLC(dilution, standard 2005, EasyOne Pro) ) / TLC(body, Vyaire) and FEV1(EasyOne Pro) / FEV1(predicted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device comparison using the same method for both devices.</measure>
    <time_frame>single measurement on day 1</time_frame>
    <description>Total Lung Capacity (TLC) (dilution, standard 2005, EasyOne Pro) / TLC(dilution, standard, Vyaire). Determines accuracy and comparability of both devices in measurement of TLC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Total-breath method followed by standard method</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Total Lung Capacity (TLC) measurement performed on device EasyOne Pro (TM) according to total-breath method followed by TLC measurement performed on device MasterScreen (TM) according to standard method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard method followed by total breath method</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Total Lung Capacity (TLC) measurement performed on device Masterscreen (TM) according to standard method followed by TLC measurement performed on device EasyOne Pro (TM) according to total-breath method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respiratory Analysis System</intervention_name>
    <description>Measurement of total lung capacity using total-breath method</description>
    <arm_group_label>Standard method followed by total breath method</arm_group_label>
    <arm_group_label>Total-breath method followed by standard method</arm_group_label>
    <other_name>EasyOne Pro (TM) by ndd Medizintechnik AG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respiratory Analysis System</intervention_name>
    <description>Measurement of total lung capacity using standard method</description>
    <arm_group_label>Standard method followed by total breath method</arm_group_label>
    <arm_group_label>Total-breath method followed by standard method</arm_group_label>
    <other_name>Masterscreen (TM) by Vyaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        3 groups&#xD;
&#xD;
          -  Healthy subjects, FEV1/FEV1(pred) &gt; 80%&#xD;
&#xD;
          -  COPD GOLD classification 1 or 2, FEV1/FEV1(pred) ≥ 50%&#xD;
&#xD;
          -  COPD GOLD classification 3 or 4, FEV1/FEV1(pred) &lt; 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoked during 2 hours prior to measurements&#xD;
&#xD;
        Additional exclusion criteria for healthy subjects:&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Any relevant concomitant diseases (investigators decision)&#xD;
&#xD;
          -  Any relevant concomitant medication (investigators decision)&#xD;
&#xD;
          -  FEV1/FEV1(pred) &lt;= 80%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LungenZentrum Hirslanden</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>DLCO</keyword>
  <keyword>spirometry</keyword>
  <keyword>alveolar volume</keyword>
  <keyword>body plethysmography</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

